Headlines

Pfizer axes new weight loss pill after patients experience serious side effects

Pfizer is discontinuing danuglipron, its twice-daily weight loss pill, after more than half of patients in a clinical trial stopped taking it.

GSK RSV vaccine revenue to reach $1.26 billion in first year, CEO says

GSK CEO Emma Walmsley has told Reuters that the company’s respiratory syncytial virus (RSV) vaccine is expected to make over $1.26 billion in its first year on the market.

Mytos co-founders Ali Afshar and Ignacio Willats

Mytos announces $19 million series A funding to automate human cell manufacturing

Mytos, a London-based automated cell manufacturing company, has closed $19 million in Series A financing led by Buckley Ventures, with participation from IQ Capital and Wing VC.

AbbVie buys ImmunoGen for $10.1 billion, expanding cancer drug portfolio

AbbVie is acquiring rival biotech firm ImmunoGen for $10.1 billion, giving it access to ImmunoGen's flagship ovarian cancer treatment Elahere, which was granted accelerated approval from the FDA last year.